Floatz logo

cd123-car-nk cells

Refractory Leukemia

Chongqing Precision Biotech Co., LtdCell therapyPhase 1/2Active
CCC
48/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
33/ 100
Competitive Position
95/ 100

Competitive context

2 Active assets in the Refractory Leukemia cohort.

Asset / SponsorPhaseRating
Visilizumab
The First Affiliated Hospital of Soochow University
Phase 3B
Olverembatinib
Institute of Hematology & Blood Diseases Hospital, China
Phase 1CC
Apg-2575
Institute of Hematology & Blood Diseases Hospital, China
Phase 1CC

Same molecule, other indications

cd123-car-nk cells is also rated in:

CD4+/CD56+ hematodermic neoplasmDormant
CCC
Indicative ·
48 / 100
View asset →
leukemiaDormant
CCC
Indicative ·
48 / 100
View asset →
acute myeloid leukemiaDormant
CC
Indicative ·
45 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →